Related coverage linked through entity extraction aliases.
Feb 28, 2026
Oral semaglutide reduced heart failure events by 22% in Type 2 diabetes patients with existing heart failure in a trial of nearly 9,650 adults, with particular benefit in HFpEF cases.
Feb 23, 2026
Study of 3600 older adults with type 1 diabetes across US and European registries reveals significant gaps in guideline-recommended cardiovascular therapies and diabetes technology use despite high disease burden.
Feb 15, 2026
Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.
Feb 13, 2026
Recent studies demonstrate tirzepatide's efficacy extends beyond diabetes management, showing reduced glaucoma risk in diabetic patients and significant improvements in pediatric Type 2 diabetes treatment with superior weight loss outcomes.
Feb 13, 2026
Real-world study finds SGLT2 inhibitors reduce chronic kidney disease and acute kidney injury risk more effectively than GLP-1 receptor agonists in patients with type 2 diabetes, with greatest benefits in those without preexisting kidney disease.
